PMID- 31502159
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20210903
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 2055
DP  - 2020
TI  - HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, 
      Functional Significance, and Clinical Relevance with Special Emphasis on Their 
      Role in T Cell-Based Immunotherapy of Malignant Disease.
PG  - 325-350
LID - 10.1007/978-1-4939-9773-2_15 [doi]
AB  - MHC class I antigen abnormalities have been shown to be one of the major immune 
      escape mechanisms murine and human cancer cells utilize to avoid recognition and 
      destruction by host immune system. This mechanism has clinical relevance, since 
      it is associated with poor prognosis and/or reduced patients' survival in many 
      types of malignant diseases. The recent impressive clinical responses to T 
      cell-based immunotherapies triggered by checkpoint inhibitors have rekindled 
      tumor immunologists and clinical oncologists' interest in the analysis of the 
      human leukocyte antigen (HLA) class I antigen processing machinery (APM) 
      expression and function in malignant cells. Abnormalities in the expression, 
      regulation and/or function of components of this machinery have been associated 
      with the development of resistances to T cell-based immunotherapies. In this 
      review, following the description of the human leukocyte antigen (HLA) class I 
      APM organization and function, the information related to the frequency of 
      defects in HLA class I APM component expression in various types of cancer and 
      the underlying molecular mechanisms is summarized. Then the impact of these 
      defects on clinical response to T cell-based immunotherapies and strategies to 
      revert this immune escape process are discussed.
FAU - Seliger, Barbara
AU  - Seliger B
AD  - Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle 
      (Saale), Germany. barbara.seliger@uk-halle.de.
FAU - Ferrone, Soldano
AU  - Ferrone S
AD  - Division of Surgical Oncology, Department of Surgery, Massachusetts General 
      Hospital, Harvard Medical School, Boston, MA, USA. sferrone@mgh.harvard.edu.
LA  - eng
GR  - R03 CA253319/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Cell- and Tissue-Based Therapy
MH  - Gene Expression Regulation, Neoplastic
MH  - Histocompatibility Antigens Class I/*genetics/*metabolism
MH  - Humans
MH  - Immunotherapy
MH  - Neoplasms/genetics/immunology/*therapy
MH  - Prognosis
MH  - T-Lymphocytes/immunology/*transplantation
MH  - Tumor Escape
OTO - NOTNLM
OT  - Antigen processing machinery
OT  - HLA class I
OT  - Immune escape
OT  - Immune response
OT  - MHC
OT  - Prognostic marker
OT  - Tumor surveillance
EDAT- 2019/09/11 06:00
MHDA- 2020/11/11 06:00
CRDT- 2019/09/11 06:00
PHST- 2019/09/11 06:00 [entrez]
PHST- 2019/09/11 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1007/978-1-4939-9773-2_15 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2020;2055:325-350. doi: 10.1007/978-1-4939-9773-2_15.